ASCO 2022 | The benefits of nivolumab and relatlimab in melanoma

Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, discusses the benefits of nivolumab and relatlimab therapy in the treatment of melanoma. Compared to nivolumab monotherapy, utilizing two immunotherapies have demonstrated benefit and despite the availability of nivolumab and ipilimumab, nivolumab and relatlimab is an effective approach for targeting patients with a high tumor burden or brain metastases. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.